Site Approval (700 JOD): Approval of Manufacturing and Warehouse Premises

1. Key takeaways

The JFDA fee schedule prices site approval at 700 JOD, the same amount as the circulation (registration) study. GRZAN’s conclusion is that this equal pricing shows that site approval carries a weight in the Jordanian regulatory system comparable to the registration review itself — it is not an ancillary procedure. In budget terms, this means a company should treat site approval not as an administrative surcharge but as a second substantive review.

• Second conclusion: site approval covers both the production end and the warehousing end. The production end corresponds to manufacturing sites under the 2011 GMP guidelines; the warehousing end corresponds to GSP warehouses under the 2019 circulation criteria. Each end carries independent approval requirements. The two approvals should be tracked as separate workstreams with separate owners.
• Third conclusion: high-risk devices and first-time applicants face a higher probability of being required to complete site approval. Companies should handle it on a may-trigger basis in their budget and timeline planning. The trigger is the reviewer’s judgement, so the plan must carry the uncertainty rather than assume it away.

2. Legal basis

The site approval requirement and its fee rest on the following instruments.

Clause numbers must be verified against the Arabic originals published in the Official Gazette of Jordan and issued by the JFDA; the amounts are the official fees listed in the JFDA fee schedule.

3. Expert insights

Insight 1: pricing site approval at 700 JOD, equal to the registration study, reflects its procedural weight. If site approval were merely a formal registration, its price would not match that of a review study. GRZAN therefore judges that site approval contains substantive on-site review content. An authority does not price a form-filling exercise at the level of a technical review; the fee therefore encodes the depth of the scrutiny.

Insight 2: the review content at the production end derives from the GMP guidelines. The review covers the entire process: design and development, purchasing, production control, inspection and testing, control of nonconforming product, corrective and preventive actions, and management review. Class III devices applying for the first time, with complex production conditions, face a higher probability of an on-site inspection being arranged. The breadth of these areas also explains why preparation cannot be improvised: the reviewer can walk into any part of the quality system.

Insight 3: the approval at the warehousing end is bound to the registration. The registration dossier links to a warehouse held in the AR’s name that has passed JFDA on-site acceptance. Warehouse acceptance is in substance the approval of the warehousing site, and the registration cannot be completed without it. For registration purposes, the warehouse is treated as part of the approved infrastructure of the product.

Insight 4: the GLP certificate is a separate qualification line. The fee schedule prices the issuance, renewal or scope extension of a GLP certificate at 1,000 JOD, the highest of the nine fees. This item is usually connected with laboratory-related qualifications and is generally not triggered by ordinary device registration. Its place in the same fee schedule is a reminder that the schedule covers the full regulatory perimeter, not only product registration.

Insight 5: site approval and the internationalisation of the JFDA reinforce each other. The JFDA has listed obtaining PIC/S membership as a priority for 2025–2027, and the core of PIC/S is precisely the mutual recognition and harmonisation of GMP inspection. The standards and frequency of site approval will tend to rise as internationalisation advances. Companies planning multi-year operations in Jordan should therefore expect site expectations to converge with international inspection practice.

4. Practical recommendations

• Reserve 700 JOD for site approval in the budget. The production end and the warehousing end may each give rise to the fee separately. The reserve should be held whether or not either approval is ultimately requested.
• Prepare the production site inspection materials along the seven areas of the GMP guidelines. Records for design and development, purchasing, production control, inspection and testing, control of nonconforming product, corrective and preventive actions, and management review should be retrievable at any time. The records should be indexed so that any of them can be produced during a visit.
• Complete the acceptance check of the warehousing site at the AR selection stage. Avoid discovering only after the AR has been chosen that the warehouse has not passed acceptance. The acceptance check should be a condition precedent in the selection decision.
• Watch the effect of the JFDA’s internationalisation progress on site standards. Plan over the long term on the assumption that standards will tighten. The trajectory matters more than any single announcement.

5. Verification checklist

• □ A 700 JOD budget line has been reserved for site approval (production end and warehousing end assessed separately)
• □ Production site inspection materials have been prepared along the seven areas of the GMP guidelines
• □ The acceptance status of the warehousing site has been checked at the AR selection stage
• □ Whether a GLP certificate (1,000 JOD) is required has been confirmed
• □ The probability of high-risk devices and first-time applications triggering production site approval has been assessed
• □ The effect of the JFDA’s internationalisation progress on site approval standards is being monitored
• □ The cited clause numbers have been re-verified against the Arabic originals of the Official Gazette

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Jordanian market. Our team coordinates local importer arrangements, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com